Tumour-targeted delivery of therapeutic nanoparticles


Nanocapture is a translational biomedical research project. Our small pre-seed team is based at the Pharmacy Department at the Ludwig-Maximilians-Universität Munich, Germany. Supported by the GO-Bio program of the German Federal Government – BMBF, our team is aiming to significantly improve the selectivity of drug delivery during tumour chemotherapies. In our key proof-of concept studies, we could demonstrate that our lead product, NanoCap-DLV, effectively slows down tumour progression in aggressive models of pancreatic and breast cancer compared to the standard of care. 


  • 2019 October - Stefanie Sperling and Kathrin Klar join team NanoCapture! Wellcome!
  • 2019 April - Constanze Heise and Monique Preuße join team NanoCapture! Wellcome!
  • 2018 August - Julia Ahlfeld joins team NanoCapture! Wellcome!
  • 2018 April - NanoCapture is one of the eight winners of the GO-Bio competition!
    The team receives the prestigious award at the German Biotechnology Days in Berlin.
  • 2017 October - NanoCapture progresses to the final selection round of the GO-Bio program.
  • 2017 June - NanoCapture submits a project proposal for the 8th round of GO-Bio,
    Germany’s most prestigious funding for translational biotech projects.
  • 2017 May - The NanoCapture team attends the BioEntrepreneur Boot Camp organized by BioM.
  • 2017 January - Dr. Thorn-Seshold and Dr. Marinković present preliminary proof-of-concept studies that showed great potential for the technology. The NanoCapture project successfully moves into the feasibility phase funded by BMBF.
  • 2015 November - Dr. Thorn-Seshold wins the Innovationsakademie competiton with a novel concept
    to improve cancer therapy - NanoCapture.


The NanoCapture is a multidisciplinary team with experts in chemistry, in vivo biology and oncology.



Project Leader

Petar brings more than 10 years of experience in leading scientific projects. Together with Dr. Thorn-Seshold, he performed first proof-of-principle studies and obtained the initial funding for the project. He is responsible for the overall project strategy, as well as for the scientific and business development.


Translational Lead

Kathrin comes to NanoCapture after successful time at Imevax, a vaccine developer, where she was one of the key people in company’s transition from preclinical validation to the phase one clinical trial. Her responsibility at NanoCapture  is to secure highest standards of preclinical work in order to move the project towards clinical phase of development.

KK Passbild


Translational research scientist

Julia is a scientist with a strong background in tumour pathology, neurobiology and molecular biology. In addition, she brings valuable experience in conducting and organizing clinical trials. Within the NanoCapture project, she is responsible for the in-house studies and data analysis.


Translational research scientist

Stefanie comes to NanoCapture after very successful PhD at Helmholtz Zentrum and TU-München. As a experienced scientist in oncology field, Stefanie is planning and running our in-house studies




in vivo assays

Constanze is a technical assistant with extensive experience in oncology research. Within the NanoCapture project, she is responsible for running in-house in vivo assays.


in vitro assays

Monique is a technical assistant and brings strong expertise in establishing and running in vitro assays.

Monique good



Oliver is the inventor of the NanoCapture concept which won the 2015 Innovationsakademie competition. With the strong  background in medicinal chemistry, his main research interest is developing more selective and powerful anticancer drugs. Oliver is a junior group leader at the Pharmacy Department at LMU and remains a close advisor to the NanoCapture project.

Do you want to be part of NanoCapture?


Get connected to NanoCapture

NanoCapture i.Gr.
LMU München
Department Pharmazie
Butenandtstr. 1
81377 München

Follow us: